{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003143","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.674583+00:00","generated_at":"2026-05-24T14:55:19.809354+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protalix increases ATM equity offering capacity by $20M for general corporate purposes","bullets":["Amendment with H.C. Wainwright increases ATM offering capacity by $20M in aggregate gross sales price.","Net proceeds will be used for general corporate purposes, including working capital and clinical trials.","Prospectus supplement filed to register additional shares under existing shelf registration statement.","No shares were previously available for sale under the existing Sales Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003143","json":"https://secwatch.observer/filing/0001558370-25-003143.json","markdown":"https://secwatch.observer/filing/0001558370-25-003143.md","text":"https://secwatch.observer/filing/0001558370-25-003143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025003143/0001558370-25-003143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025003143/plx-20250317x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:55:19.809354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}